Biofrontera (BFRI) Convertible Debt (2024 - 2025)
Biofrontera's (BFRI) quarterly Convertible Debt came in at $4.6 million in Q4 2025, up 11.98% year-on-year from $4.1 million in Q4 2024, and up 2.85% quarter-over-quarter from $4.5 million in Q3 2025.
Biofrontera (BFRI) Convertible Debt (2024 - 2025) Analysis & Trends
Biofrontera's Convertible Debt history runs 2 years deep, the most recent figure standing at $4.6 million for Q4 2025.
- On a quarterly basis, Convertible Debt rose 11.98% year-over-year to $4.6 million in Q4 2025; TTM through Dec 2025 was $4.6 million, a 11.98% increase from a year earlier, with the FY2025 full-year figure at $4.6 million, up 11.98% from the prior year.
- Convertible Debt grew to $4.6 million in Q4 2025 per BFRI's latest filing, from $4.5 million in the prior quarter.
- Across five years, Convertible Debt topped out at $4.6 million in Q4 2025 and bottomed at $4.1 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Biofrontera | 12.70 Mn | 6.29 Mn | 14.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.59 Mn |
| Sep 30, 2025 | 4.46 Mn |
| Jun 30, 2025 | 4.34 Mn |
| Mar 31, 2025 | 4.22 Mn |
| Dec 31, 2024 | 4.10 Mn |